Rod Rohrich is one of the leading plastic surgeons in the world. He is the Editor in Chief of the Journal of Plastic and Reconstructive Surgery, the leading journal in the field. He is a founding member of the world famous Dallas Plastic Surgery Institute and served as the Founder and first Chair of the Plastic Surgery Department at the University of Texas Southwestern Medical Center that he developed into a global powerhouse for training excellence in plastic surgery . He has also chaired and been president of numerous professional organizations, including the American Society of Plastic Surgeons, which is the largest society of board-certified Plastic Surgeons in the world. Dr. Rohrich has a global practice at Dallas Plastic Surgery Institute, and publishes extensively, does clinical research trials, and lectures frequently around the globe. He was one of the first in plastic surgery to recognize the important role of Tranexamic Acid in aesthetic surgery. He has done clinical research and lectured extensively on the use of TA in aesthetic surgical procedures, and has pioneered its use in non-surgical procedures.
Rod J. Rohrich, M.D.
David C. Bloom, Ph.D.
Dave Bloom is a Professor of Molecular Genetics and Microbiology in the College of Medicine at the University of Florida. He is one of the leading authorities in the world on Herpes Simplex Virus. His lab has conducted extensive in vitro and in vivo research regarding the use of Tranexamic Acid against HSV, including effects on genetic transcription and TA’s ability to inhibit production of drug-resistant mutants. His research has also included synergistic combinations of TA with acyclovir and docosanol, the leading drugs currently used against HSV, as well as examination of TA as a general serine protease inhibitor and the relevance of that issue for multiple types of virus.
Brian K. Law, Ph.D.
Brian Law is an Associate Professor in the Department of Pharmacology and Therapeutics in the College of Medicine at the University of Florida. He has particular expertise in breast cancer, and is involved in the development of a novel class of anti-cancer agents called Disulfide Bond Disrupting Agents (DDAs). He has also conducted extensive in vitro and in vivo research regarding the use of Tranexamic Acid against multiple types of cancer, alone and in combination with the DDAs.
Ronald K. Castellano, Ph.D.
Ron Castellano is a Professor in the Chemistry Department at the University of Florida and leads the Castellano Research Group laboratory focused on supramolecular chemistry. He has collaborated with researchers in the UF College of Medicine to design and study novel therapeutics (antihypertensives and anticancer agents), including work on creating the Disulfide Bond Disrupting Agents (DDAs) as a unique class of drugs to combat breast cancer tumorigenesis. He has been involved in developing and testing the Tranexamic Class Antagonists (TXCAs) of the positively charged amino acids, based on current and new analogs of lysine, arginine, and histidine.
Matthew D Reed, Ph.D., DABT, Fellow ATS
Matt Reed has over 25 years of experience in pharmacology, toxicology, and nonclinical development, including 18 years at well-known Lovelace Biomedical. He has overseen and consulted on drug delivery (including to the respiratory system), applied toxicology studies, formulation feasibility and development, pharmacokinetics, pharmacology, safety pharmacology, and pivotal IND and NDA GLP compliant studies. He has consulted particularly on the creation and study of the Tranexamic Acid nasal spray for respiratory viruses.